Champions Oncology, Ichan School of Medicine, and Mount Sinai Hospital Jointly Present at San Antonio Breast Cancer Symposium
Hackensack, NJ – December 9, 2014 – Champions Oncology Inc. (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced preliminary data derived from correlating patient-derived xenograft (PDX) models and their ability to predict patient response to drug treatment in a cohort of breast cancer patients will be presented at the San Antonio Breast Cancer Symposium.
The data, the result of collaboration between the Ichan School of Medicine at Mount Sinai and Champions Oncology initiated earlier this year, are the first from an ongoing clinical trial evaluating the use of Champions TumorGraft® PDX models in 100 patients with triple-negative breast cancer. The study also includes a side-by-side genomic analysis of the patients’ tumors and the PDX models before and after treatment, which are compared to evaluate how closely the models continue to resemble the patients’ progress.
Champions TumorGraft PDX models are a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient’s living tumor is removed during surgery or biopsy and engrafted in immune-deficient mice. After the PDX model grows, still closely resembling the patient’s tumor, Champions Oncology tests drug treatment in the model and measures the response. Champions TumorGraft PDX models have demonstrated high rates of predictability using multiple therapies, including single-agent and combination, chemotherapy regimens and targeted biological drugs, with data previously published in Cancer and Cancer Clinical Research.
Banked Champions TumorGraft PDX models can be re-grown and tested in the event of cancer progression or recurrence. They have successfully be utilized in most sold tumor types including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal, and others.